Filtered By:
Condition: Heart Attack
Management: Funding

This page shows you your search results in order of date.

Order by Relevance | Date

Total 99 results found since Jan 2013.

News at a glance: A win for obesity drugs, NIH unionization roadblocks, and Mexican fireflies under threat
CONSERVATION Researchers raise alarm over threat to Mexican fireflies Scientists from the International Union for Conservation of Nature (IUCN) last week delivered a letter to the Mexican government requesting it regulate tourism centered on the threatened firefly species Photinus palaciosi . Endemic to Mexico’s Tlaxcala forests, P. palaciosi is one of the few species that glow in synchrony, offering an annual spectacle that attracts thousands of visitors during summer mating season. The letter describes how littering, artificial light, and noise interfere with the insects’ courtship and eg...
Source: ScienceNOW - August 10, 2023 Category: Science Source Type: news

News at a glance: A win for obesity drugs, a new infectious disease institute head, and Mexican fireflies under threat
CONSERVATION Researchers raise alarm over threat to Mexican fireflies Scientists from the International Union for Conservation of Nature (IUCN) last week delivered a letter to the Mexican government requesting it regulate tourism centered on the threatened firefly species Photinus palaciosi . Endemic to Mexico’s Tlaxcala forests, P. palaciosi is one of the few species that glow in synchrony, offering an annual spectacle that attracts thousands of visitors during summer mating season. The letter describes how littering, artificial light, and noise interfere with the insects’ courtship and eg...
Source: Science of Aging Knowledge Environment - August 10, 2023 Category: Geriatrics Source Type: research

Assessing statins use in a real-world primary care digital strategy: a cross-sectional analysis of a population-wide digital health approach
Lancet Reg Health Am. 2023 Jun 22;23:100534. doi: 10.1016/j.lana.2023.100534. eCollection 2023 Jul.ABSTRACTBACKGROUND: The digitization of the primary care system provides an opportunity to evaluate the current use of statins in secondary prevention populations (myocardial infarction or stroke).METHODS: We conducted a cross-sectional study (ClinicalTrials.gov, NCT05285085), analysing anonymised data routinely collected by community health workers (CHW) in Brazil between May 2016 and September 2021 to assess the proportion of self-reported statins use and associated factors.FINDINGS: From the 2,133,900 individuals on the da...
Source: Atherosclerosis - July 27, 2023 Category: Cardiology Authors: M Julia Machline-Carrion Alysson Nathan Girotto Josu é Nieri Pedro Marton Pereira Frederico Monfardini Francisco Forestiero Priscila Raupp Fabiana Roveda Karla Santo Ot ávio Berwanger Raul D Santos Source Type: research

The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial
This study was registered with the German Clinical Trials Register, DRKS00015322.FINDINGS: Between Jan 1, 2019 and Dec 22, 2020, 36 clusters were assessed for eligibility, of which 30 were randomly assigned to the intervention group (n=15 clusters) or control group (n=15 clusters). No clusters dropped out of the study. 1203 (86%) of 1396 enrolled patients in the intervention group and 1283 (92%) of 1395 enrolled patients in the control group were included in the mITT population. The primary endpoint was confirmed in 64 (5·3%) of 1203 patients in the intervention group and 80 (6·2%) of 1283 patients in the control group (...
Source: Cancer Control - July 17, 2023 Category: Cancer & Oncology Authors: Christopher J Schwarzbach Felizitas Anna Eichner Viktoria R ücker Anna-Lena Hofmann Moritz Keller Heinrich J Audebert Stephan von Bandemer Stefan T Engelter Dieter Geis Klaus Gr öschel Karl Georg Haeusler Gerhard F Hamann Andreas Meisel Dirk Sander Mart Source Type: research

New Urban Health ‘Accelerator’ Aims to Transform Cardiovascular Population Health Globally
ihadmin2May 22, 2023May 22, 2023GenevaThe CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.Results of initial programs in S ão Paulo, Dakar and Ulaanbaatar show the cost-effective approach averted up to 13% of strokes and 12% of heart attacks during implementation.Experts say public-private partnerships are key to address the growing burden of cardiovascular disease, the world ’s leading cause of death,according to the World Health O...
Source: IntraHealth International - May 22, 2023 Category: International Medicine & Public Health Authors: ihadmin2 Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

How AI Is Changing Medical Imaging to Improve Patient Care
That doctors can peer into the human body without making a single incision once seemed like a miraculous concept. But medical imaging in radiology has come a long way, and the latest artificial intelligence (AI)-driven techniques are going much further: exploiting the massive computing abilities of AI and machine learning to mine body scans for differences that even the human eye can miss. Imaging in medicine now involves sophisticated ways of analyzing every data point to distinguish disease from health and signal from noise. If the first few decades of radiology were about refining the resolution of the pictures taken of...
Source: TIME: Health - November 4, 2022 Category: Consumer Health News Authors: Alice Park and Video by Andrew D. Johnson Tags: Uncategorized Frontiers of Medicine 2022 healthscienceclimate Innovation sponsorshipblock Source Type: news

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research

The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors
N Z Med J. 2022 Aug 19;135(1560):99-104.ABSTRACTThe sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout. Patients with or without diabetes who have a history of heart failure, including those with a preserved left ventricular ejection fraction and patients with ch...
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Chok G Chan Ralph Stewart Source Type: research